EADV 2025: Interim Real-World Data from ADlife on Lebrikizumab in Moderate-to-Severe AD
New interim real-world data from the ADlife study explore the effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis. Early results at weeks 4 and 16 suggest promising clinical outcomes in a comorbid, treatment-experienced population.
Image courtesy of the European Academy of Dermatology and Venereology (EADV).
